Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions.
PMID 39759507 · PMC11695424 · Frontiers in immunology · 2024 · 8 claims · 8 setups
A malignant cell subtype in PCa with high expression of NEFH was identified, located at the differentiation terminal, showing higher malignancy and association with advanced tumor lesions.
-
Has reproduction · 70
Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.
PMID 36450752 · PMC9712620 · Nature communications · 2022 · 8 claims · 8 setups
AR chromatin binding is highly heterogeneous between primary prostate tumors, with <5% of all AR binding sites (ARBS) shared by half of the 88 tumors analyzed
-
Full-text index only
A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules.
PMID 41534092 · PMC13044530 · Cancer research · 2026 · 8 claims · 8 setups
SWI/SNF-targeting PROTAC treatment reduces viability of CRPC-WNT (AR-negative) cell lines and organoids, not just AR-dependent CRPC
-
Full-text index only
CRISPR screens in the context of immune selection identify CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance.
PMID 41564866 · PMC12866162 · Cell reports. Medicine · 2026 · 8 claims · 8 setups
CHD1 and MAP3K7 loss additively sensitizes cancer cells to IFN-γ-induced death